Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $215.8 million.

  • Enanta Pharmaceuticals' Total Non-Current Liabilities fell 1286.39% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year decrease of 1286.39%. This contributed to the annual value of $215.8 million for FY2025, which is 1286.39% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $215.8 million for Q3 2025, which was down 1286.39% from $221.5 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities peaked at $256.9 million during Q2 2023, and registered a low of $30.7 million during Q1 2021.
  • Its 5-year average for Total Non-Current Liabilities is $147.0 million, with a median of $215.8 million in 2025.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Total Non-Current Liabilities crashed by 1638.73% in 2022, and later skyrocketed by 44957.01% in 2023.
  • Enanta Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $55.4 million in 2021, then fell by 16.39% to $46.3 million in 2022, then soared by 409.83% to $236.0 million in 2023, then grew by 0.26% to $236.6 million in 2024, then fell by 8.81% to $215.8 million in 2025.
  • Its Total Non-Current Liabilities stands at $215.8 million for Q3 2025, versus $221.5 million for Q2 2025 and $229.2 million for Q1 2025.